TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

TRACON Pharmaceuticals (NASDAQ: TCON) announced that CEO Charles Theuer will present a corporate overview at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 3:10 PM ET. The presentation will focus on TRACON's innovative cancer therapeutics and their cost-efficient, CRO-independent development platform. The company’s pipeline includes Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. Investors can access the event via the TRACON website.

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021 at 3:10pm Eastern Time.

To access a live webcast of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:	Investor Contact:
Mark Wiggins	Brian Ritchie
Chief Business Officer	LifeSci Advisors LLC
(858) 251-3492	212-915-2578
mwiggins@traconpharma.com	britchie@lifesciadvisors.com

FAQ

What is TRACON Pharmaceuticals presenting at the Oppenheimer Healthcare Conference on March 16, 2021?

TRACON Pharmaceuticals will present a corporate overview highlighting its cancer therapeutics and product pipeline.

Who is the CEO of TRACON Pharmaceuticals?

Charles Theuer is the President and CEO of TRACON Pharmaceuticals.

What is the focus of TRACON Pharmaceuticals' product pipeline?

TRACON focuses on developing targeted cancer therapies, including Envafolimab, TRC253, TRC102, and TJ004309.

How can I access the live webcast of TRACON Pharmaceuticals' presentation?

You can access the live webcast on the 'Events and Presentations' page within the 'Investors' section of TRACON's website.

What date and time is TRACON Pharmaceuticals' presentation at the conference?

TRACON's presentation is scheduled for March 16, 2021, at 3:10 PM Eastern Time.